Literature DB >> 19829013

Retinal ganglion cell death postponed: giving apoptosis a break?

Lilian Kisiswa1, Adrian G Dervan, Julie Albon, James E Morgan, Michael A Wride.   

Abstract

Glaucoma is characterised by the preferential death of retinal ganglion cells (RGCs). However, mammalian models indicate that neurons pass through a period in which they manifest signs of neuronal damage, but have yet to fully commit to death. Mounting evidence suggests that one of the clearest indications of this process is the reduction in RGC dendritic arborisation, resulting in functional compromise. The extent to which this may be reversible is unclear, since the molecular events that precede changes in dendritic structure have received little attention. Furthermore, there are likely to be many factors involved in this process potentially acting in different individual cells at different times. Recent work in Drosophila shows that dendritic reorganisation/remodelling involves local activation and tight regulation of caspase activity. Here, we propose a model in which the balance between caspases and inhibitors of apoptosis (IAPs) contributes towards the regulation of dendritic remodelling. Thus, RGC dendrite reorganisation and cell death represent opposite ends of a spectrum of events regulated by apoptosis signalling pathways. We summarise relevant events in apoptosis, focusing on caspases and IAPs. We also discuss mechanisms of dendrite development, structure and reorganisation and the implications for early diagnosis and treatment of glaucoma and neurodegenerative disease. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19829013     DOI: 10.1159/000247591

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  7 in total

Review 1.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 2.  Pharmacotherapy of glaucoma.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  J Ocul Pharmacol Ther       Date:  2015-01-14       Impact factor: 2.671

3.  Semi-automated, quantitative analysis of retinal ganglion cell morphology in mice selectively expressing yellow fluorescent protein.

Authors:  Ericka Oglesby; Harry A Quigley; Donald J Zack; Frances E Cone; Matthew R Steinhart; Jing Tian; Mary E Pease; Giedrius Kalesnykas
Journal:  Exp Eye Res       Date:  2011-12-22       Impact factor: 3.467

4.  Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure.

Authors:  Tamotsu Seki; Hiroyuki Itoh; Tomoya Nakamachi; Kimi Endo; Yoshihiro Wada; Keisuke Nakamura; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2010-06-29       Impact factor: 3.444

5.  Calcium-permeable AMPA receptors in the retina.

Authors:  Jeffrey S Diamond
Journal:  Front Mol Neurosci       Date:  2011-09-26       Impact factor: 5.639

6.  Ocular neuroprotection by siRNA targeting caspase-2.

Authors:  Z Ahmed; H Kalinski; M Berry; M Almasieh; H Ashush; N Slager; A Brafman; I Spivak; N Prasad; I Mett; E Shalom; E Alpert; A Di Polo; E Feinstein; A Logan
Journal:  Cell Death Dis       Date:  2011-06-16       Impact factor: 8.469

7.  The role of peroxisome proliferator-activated receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush: PPARγ in retinal neuroprotection.

Authors:  Juming Zhu; Junfang Zhang; Min Ji; Hongwei Gu; Yue Xu; Chen Chen; Nan Hu
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.